Routine board appointment with no immediate trading implications. Monitor for any future scientific or strategic developments tied to Dr. Greka's expertise in kidney disease and biotech venture advisory.
Price Chart
Executive Summary
Ovid Therapeutics appointed Dr. Anna Greka, a Harvard Medical School professor and Broad Institute executive, as a Class III director effective June 15, 2026, expanding the board to seven members. This is a routine board appointment with no material financial impact.
Key Facts
- Board expanded from six to seven directors effective June 15, 2026
- Dr. Anna Greka appointed as Class III director with term expiring at 2029 annual meeting
- Dr. Greka also appointed to Compensation Committee and Science and Technology Committee
- Dr. Greka is Professor of Medicine at Harvard Medical School and holds leadership roles at Broad Institute
- Compensation follows standard non-employee director policy; standard indemnification agreement entered
Financial Impact
No financial figures disclosed; compensation is standard non-employee director policy
Risk Factors
- No material risks identified from this filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-040038 |
| Document: 0001628280-26-040038-index-headers.html | 0001628280-26-040038 |
| Document: 0001628280-26-040038-index.html | 0001628280-26-040038 |
| Document: 0001628280-26-040038.txt | 0001628280-26-040038 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 10w ago | 144 | $2.89 | awaiting T+60 | — | $2.15 (−25.43%) |
Jul 8, 2026 15w ago | 8-K | $2.73 $2.49 | ▼ −8.79% | ▼ −11.10% | $2.15 (−21.06%) |
Jun 3, 2026 20w ago | 8-K | $2.39 $2.93 | ▲ +22.59% | ▲ +20.10% | $2.15 (−9.83%) |
May 12, 2026 23w ago | Press Release | $2.87 $2.65 | ▼ −7.67% | ▼ −12.05% | $2.15 (−24.91%) |
Apr 27, 2026 26w ago | EFFECT | $2.69 $2.38 | ▼ −11.52% | ▼ −16.30% | $2.15 (−19.89%) |
Apr 21, 2026 26w ago | S-3 | $2.66 $2.44 | ▼ −8.27% | ▼ −13.05% | $2.15 (−18.98%) |
Apr 20, 2026 27w ago | 8-K | $2.89 $2.49 | ▼ −13.84% | ▼ −20.62% | $2.15 (−25.43%) |
Mar 18, 2026 31w ago | 8-K | $2.30 $2.21 | ▼ −3.91% | ▼ −15.44% | $2.15 (−6.30%) |
Mar 18, 2026 31w ago | Press Release | $2.30 $2.21 | ▼ −3.91% | ▼ −15.44% | $2.15 (−6.30%) |
Mar 18, 2026 31w ago | Press Release | $2.30 $2.21 | ▼ −3.91% | ▼ −15.44% | $2.15 (−6.30%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers